ReviewDrugs2019
Brexpiprazole: A Review in Schizophrenia.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 53 citations in OpenAlex.
- Advancements in Managing Schizophrenia through Classical Approaches, Mechanisms, and Deep Brain Stimulation.Current pharmaceutical design · 2025Review
- Brexpiprazole inhibits EMT and migration of colorectal cancer cells by downregulating the SREBP1/SNAI1 signaling pathway.Frontiers in oncology · 2025Article
- Treatment satisfaction and effectiveness of Lurasidone on quality of life and functioning in adult patients with schizophrenia in the real-world Italian clinical practice: a prospective 3-month observational study.Annals of general psychiatry · 2024Article
- Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series.Medicina (Kaunas, Lithuania) · 2024Article
- Construction and evaluation of a phospholipid-based phase transition in situ gel system for brexpiprazole.Drug delivery and translational research · 2023Article
- Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update.Current neuropharmacology · 2023Review
- New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression.International journal of molecular sciences · 2022Review
- Neurotransmitters: Potential Targets in Glioblastoma.Cancers · 2022Review
- Brexpiprazole blocks post-traumatic stress disorder-like memory while promoting normal fear memory.Molecular psychiatry · 2021Article
- Effects of Atypical Antipsychotics, Clozapine, Quetiapine and Brexpiprazole on Astroglial Transmission Associated with Connexin43.International journal of molecular sciences · 2021Article
- Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics.RSC advances · 2021Article
- Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia.Brain sciences · 2020Review
- Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.CNS drugs · 2020Review
- Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia.The international journal of neuropsychopharmacology · 2019Article
- Brexpiprazole as a New Serotonin-Dopamine Receptor Modulator: Considering the Clinical Relevance for Metabolic Parameters and Prolactin Levels.Innovations in clinical neuroscience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brexpiprazole (Rxulti
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.